AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$CBIO

McNeill Jonathan sold $77K of CBIO

McNeill Jonathan (President and COO) sold 4,570 shares of CRESCENT BIOPHARMA, INC. (CBIO) at an average of $16.90 ($16.71–$17.90) across 2 trades over 2026-09-16 to 2026-09-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McNeill Jonathan
Published Sep 18, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CBIO
Neutral
medium confidence
Mentioned
$CBIO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBIONeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, offering new data for traders monitoring insider activity.

02

Market read

Primary relevance is the insider sale; limited broader market effect.

03

What to watch

Potential upcoming clinical data releases could outweigh the effect of this small insider sale.

Relevance 2/10Novelty 4/10Timing: filing date 2026-09-18

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

$CBIONeutralMedium confidence
Context

President and COO Jonathan McNeill sold 4,570 shares for $77K via a 10b5‑1 plan, reducing his stake to 134,588 shares.

Expected impact

possible modest downside pressure

Evidence & confidence

Sale size is small relative to market cap; typical for 10b5‑1 plans, but any insider sell can trigger short‑term sell‑off.

Market effects

Sector

Minimal impact on biotech sector; isolated insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be routine; investors may ignore and focus on fundamentals.

Key entities

  • Company
    Crescent Biopharma, Inc.

    Biotech firm listed on Nasdaq.

  • Insider
    Jonathan McNeill

    President and COO of Crescent Biopharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CBIO insider trading history →

Related articles

JUL 30
$CBIOMed

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treate

SEC EDGAR 8-K4 min
JUL 14
$CBIOLow

CRESCENT BIOPHARMA, INC. (CBIO): Results of Operations and Financial Condition

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. cbio-20260714 0001253689 false 0001253689 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________________________________________________ FORM 8-K ______________________________________

SEC EDGAR 8-K1 min